4-methylacetanilide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
4-acetamidotoluene : A member of the class of toluenes that is 4-aminotoluene in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 7684 |
| CHEMBL ID | 1604472 |
| CHEBI ID | 143108 |
| SCHEMBL ID | 61417 |
| SCHEMBL ID | 12309457 |
| MeSH ID | M0581222 |
| Synonym |
|---|
| n-(p-tolyl)-acetamide |
| wln: 1vmr d1 |
| 4-methylacetanilide |
| n-acetyl-p-toluidine |
| p-acetotoluide |
| 103-89-9 |
| p-acetamidotoluene |
| nsc7644 |
| 1-acetamido-4-methylbenzene |
| n-acetyl-p-toluidide |
| n-(4-methylphenyl)acetamide |
| p-acetotoluidide |
| acetamide, n-(4-methylphenyl)- |
| p-methylacetanilide |
| 4-acetotoluide |
| 4-(acetylamino)toluene |
| nsc-7644 |
| acetyl-p-toluidine |
| AH-034/32844007 |
| n-(p-tolyl)acetamide |
| NCGC00091129-01 |
| 4-acetotoluidide |
| 4'-methylacetanilide |
| ai3-01428 |
| einecs 203-155-4 |
| nsc 7644 |
| ccris 5956 |
| inchi=1/c9h11no/c1-7-3-5-9(6-4-7)10-8(2)11/h3-6h,1-2h3,(h,10,11) |
| yicamjwhiumfdi-uhfffaoysa- |
| 4'-methylacetanilide, 99% |
| A0064 |
| p-acetotoluidine |
| smr001370915 |
| MLS002415754 |
| 4-acetamidotoluene |
| CHEBI:143108 |
| AKOS000120002 |
| NCGC00091129-02 |
| unii-n36d4jn82t |
| n36d4jn82t , |
| HMS3039J04 |
| dtxcid104414 |
| NCGC00257673-01 |
| dtxsid6024414 , |
| tox21_200119 |
| cas-103-89-9 |
| STL163784 |
| FT-0619053 |
| acetyl-p-toluidine, n- |
| p-acetotoluide [mi] |
| acetamidotoluene, p- |
| n-p-tolylacetamide |
| SCHEMBL61417 |
| SCHEMBL12309457 |
| CHEMBL1604472 |
| BS-3827 |
| acet-p-toluidide |
| W-108834 |
| F1962-0207 |
| mfcd00008677 |
| n-acetyl-para-toluidine |
| Z28134680 |
| SY035719 |
| 4 inverted exclamation mark -methylacetanilide |
| Q27284480 |
| n-(4-methyl-phenyl)acetamide |
| 2-(3-bromophenoxy)pyridine97+% |
| CS-0063380 |
| EN300-15544 |
| 4-methyl acetyl aniline |
| Class | Description |
|---|---|
| toluenes | Any member of the class of benzenes that is a substituted benzene in which the substituents include one (and only one) methyl group. |
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 35.4813 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| AR protein | Homo sapiens (human) | Potency | 16.8058 | 0.0002 | 21.2231 | 8,912.5098 | AID743040; AID743042 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 43.5709 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 3.8257 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.62) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||